ArticleEuropean journal of nuclear medicine and molecular imaging2025

Correction to: The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro‑entero‑pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu‑DOTATATE.

Marco Maccauro et al.PubMed ↗Publisher ↗

No numbers read from the abstract.